The median (95% CI) OS in patients with KRASG12C-positive vs KRAS WT cancer treated with chemotherapy alone was 10.2 (8.0-12.5) months vs 8.3 (7.4-9.4) months (aHR, 0.92; 95% CI, 0.77–1.10; p = 0.37). Here, KRAS is linked to cancer.